Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (5y) (2016 - 2026)
Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - |
| 10 | Halozyme Therapeutics | 9.85 Bn | 9.53 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.35% |
| Dec 31, 2025 | -6.37% |
| Sep 30, 2025 | -5.77% |
| Jun 30, 2025 | 50.81% |
| Mar 31, 2025 | 121.98% |
| Dec 31, 2024 | 45.40% |
| Sep 30, 2024 | 40.02% |
| Jun 30, 2024 | 46.92% |
| Mar 31, 2024 | 87.07% |
| Dec 31, 2023 | 328.38% |
| Sep 30, 2023 | 39.57% |
| Jun 30, 2023 | 47.56% |
| Mar 31, 2023 | 35.76% |
| Dec 31, 2022 | -6.71% |
| Sep 30, 2022 | 50.03% |
| Jun 30, 2022 | 34.40% |
| Mar 31, 2022 | 60.09% |
| Dec 31, 2021 | 54.57% |
| Sep 30, 2021 | 64.25% |
| Jun 30, 2021 | 71.49% |